← Human Trials & Peer-Reviewed Studies
Changes in brain natriuretic peptide levels and bioelectrical impedance measurements after treatment with high-dose furosemide and hypertonic saline solution versus high-dose furosemide alone in refractory congestive heart failure: a double-blind study
Plain-language guide to PMID 15963399 (2005): double-blind randomized controlled trial study of BNP (Nesiritide) in 94 patients.
Key Facts
- PMID
- 15963399
- Journal
- Journal of the American College of Cardiology
- Year
- 2005
- Study type
- Randomized Controlled Trial
- Authors
- Paterna S et al. (9 authors)
- DOI
- 10.1016/j.jacc.2005.01.059
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at BNP (Nesiritide).
The aim of this study was to evaluate the effect of a new treatment for refractory congestive heart failure (CHF) on brain natriuretic peptide (BNP) plasma levels and hydration station.
Who Took Part
The study group was 94 patients.
The age groups tagged for this paper are middle-aged adults, older adults and people over 80, both men and women.
A total of 94 patients (34 women/60 men) with refractory CHF (age 55 to 80 years) were enrolled.
How the Study Was Run
In design terms this was a randomized and double-blind study.
Random assignment meant chance, not the researchers, decided who got BNP (Nesiritide) and who got the comparison, which limits bias.
Neither the patients nor the staff measuring them knew who was on BNP (Nesiritide), so expectations could not easily colour the readings.
At entry, body weight, blood pressure, heart rate, and laboratory parameters were checked during hospitalization; BNP levels were measured on admission, 6 and 30 days after discharge, while on admission and 6 days after, impedance plethysmography was performed.
Fluid intake of 1,000 was given to both groups.
What Was Measured
The subject headings attached to it are Diuretics, Electric Impedance, Furosemide, Heart Failure, Natriuretic Peptide, Brain and Saline Solution, Hypertonic.
What This Means in Plain Language
The paper is a randomized and double-blind study of BNP (Nesiritide) in 94 patients.
Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2005 (Journal of the American College of Cardiology), a journal based in United States.
More context: the BNP (Nesiritide) compound page, all human trials.
Our Notes on the Compound
BNP (Nesiritide): B-type natriuretic peptide, a 32-amino-acid heart hormone; nesiritide (Natrecor) is a recombinant form used in acute heart failure.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.